Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 4Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 24Stomach Neoplasms 5Rectal Neoplasms 5Neoplasm Metastasis 5Colonic Neoplasms 5Carcinoma, Hepatocellular 4Cholangiocarcinoma 3Biliary Tract Neoplasms 3Adenocarcinoma Of Esophagus 3Unresectable Metastatic Colorectal Cancer 2Recurrence 2Neoplastic Cells, Circulating 2Neoplasms 2Gastrointestinal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Ovarian Neoplasms 1Oligometastatic Gastric Adenocarcinoma 1Neoplasms, Second Primary 1Neoplasm, Residual 1Margins of Excision 1Lung Neoplasms 1Locally-advanced Rectal Cancer 1Locally Advanced Colorectal Carcinoma 1Hyperthermia 1Gastroesophageal Junction Adenocarcinoma 1Gastroesophageal Adenocarcinoma 1Gallbladder Neoplasms 1

Interventions

pembrolizumab 16Radiotherapy 15Drug Therapy 14Paclitaxel 13Cisplatin 12Carboplatin 10Immunotherapy 9Esophagectomy 9Radiation 8Fluorouracil 8Surgical Procedures, Operative 7Capecitabine 7Blood Specimen Collection 7Oxaliplatin 6Nivolumab 6Immune Checkpoint Inhibitors 6Chemoradiotherapy 6nimotuzumab 5Trastuzumab 5130-nm albumin-bound paclitaxel 5sintilimab 4camrelizumab 4Leucovorin 4trastuzumab deruxtecan 3tislelizumab 3patritumab deruxtecan 3Surveys and Questionnaires 3Endoscopy 3Bevacizumab 3toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Esophageal Neoplasms × Folfox protocol × Clear all
NCT03526835 2025-01-29

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Merus B.V.

Phase 1/2 Recruiting
523 enrolled
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡